Pull to refresh
Logo
What Changed
Following Why Sign Up
Eli Lilly's EloraTZP combination shows greater weight loss than tirzepatide alone

Eli Lilly's EloraTZP combination shows greater weight loss than tirzepatide alone

New Capabilities

In a 48-week trial, the combination of eloralintide and tirzepatide cut weight by up to 23.3% in adults with obesity and type 2 diabetes

October 14th, 2026: Lilly VP urges patient-specific weight targets

Overview

Updated Oct 18

Adults with obesity and type 2 diabetes who took Eli Lilly's experimental EloraTZP lost an average of 23.3% of their body weight over 48 weeks — well beyond the 14.8% lost by those on tirzepatide alone, the drug sold as Zepbound. The combination pairs tirzepatide, a dual GIP and GLP-1 receptor agonist, with eloralintide, a selective amylin receptor agonist, engaging three appetite-regulating hormone pathways at once.

The results, presented September 30 at the European Association for the Study of Diabetes meeting in Milan, cleared the way for Lilly to start Phase 3 trials by the end of 2026. On October 14, Lilly metabolic chief Thomas Seck told a Seoul conference that doctors need patient-specific target weights as drugs cut weight by 30%. He cited eloralintide as a candidate with fewer gastrointestinal side effects than existing GLP-1 drugs, pending Phase 3 confirmation.

Why it matters

If it reaches market, EloraTZP would give patients a once-weekly shot that outpaces today's best-selling obesity drugs.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

23.3%
Average weight loss at 48 weeks (highest EloraTZP dose)
About 24.5 kg (54 lbs) from a mean starting weight of 105.4 kg. The highest arm paired 9 mg eloralintide with 15 mg tirzepatide.
14.8%
Average weight loss with tirzepatide 15 mg alone
The comparison arm in the same Phase 2b trial.
12.3%
Average weight loss with eloralintide alone
Highest single-agent dose in the same Phase 2b trial, versus 23.3% for the combination.
2.9%
Average A1C reduction (highest EloraTZP dose)
HbA1c, a blood sugar measure, fell 2.9% versus 2.4% for tirzepatide alone and 0.3% for placebo.
27%
Highest participant dropout from side effects on EloraTZP
Gastrointestinal effects led 10.8% to 27.0% of EloraTZP patients to leave; tirzepatide alone was 2.9%.
367
Phase 2b trial participants
Adults in the US and Argentina with obesity or overweight plus type 2 diabetes.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Dan Skovronsky
Dan Skovronsky
Chief scientific officer, Eli Lilly
Leading Lilly's research programs including obesity drug development
 Lora Heisler
Lora Heisler
Researcher, University of Aberdeen
Commenting on EloraTZP results she did not participate in
 Kevin Gade
Kevin Gade
Chief operating officer at Bahl & Gaynor
Portfolio manager commenting on trial results
TS
Thomas Seck
Senior vice president for clinical development of cardiovascular and metabolic diseases, Eli Lilly
Pushing for patient-specific weight targets; pointing to eloralintide's tolerability as a potential advantage

Organizations Involved

Eli Lilly and Company
Eli Lilly and Company
Pharmaceutical company
Advancing EloraTZP to Phase 3 trials

US drugmaker that makes Zepbound and Mounjaro (tirzepatide) and is developing EloraTZP.
Novo Nordisk
Novo Nordisk
Pharmaceutical company
On track to launch CagriSema early 2027

Danish drugmaker whose semaglutide drugs Wegovy and Ozempic created the modern obesity treatment market.

Timeline

February 2026 October 2026

4 events Latest: October 14th, 2026 · 4 weeks ago
Tap a bar to jump to that date

  1. Lilly VP urges patient-specific weight targets

    Latest Clinical development

    In a keynote at the KoNECT International Conference on Clinical Trials in Seoul, Lilly's Thomas Seck said doctors need patient-specific target weights rather than broad percentage goals, citing a tirzepatide maintenance trial. He pointed to eloralintide as a candidate with fewer gastrointestinal side effects than existing GLP-1 drugs, pending Phase 3 confirmation.

  2. EloraTZP beats tirzepatide alone in Phase 2b

    Clinical trial results

    At the EASD meeting in Milan, Lilly reported adults with obesity and type 2 diabetes on the highest EloraTZP dose lost 23.3% of their weight and cut A1C by 2.9% at 48 weeks, versus 14.8% and 2.4% for tirzepatide 15 mg alone.

  3. Lilly maps Phase 3 for EloraTZP

    Development plans

    Lilly said it will start Phase 3 trials of a co-formulated, once-weekly EloraTZP injection by the end of Q4 2026, using an adjusted dose-escalation schedule meant to cut gastrointestinal side effects.

  4. CagriSema falls short of tirzepatide in head-to-head trial

    Competitive results

    Novo Nordisk's amylin-GLP-1 combination showed about 23% average weight loss over 84 weeks but failed to beat high-dose tirzepatide, dampening expectations for the first two-drug obesity treatment.

Scenarios

1

EloraTZP starts Phase 3 by end of 2026

Likely Resolves by Q1 2027

Discussed by: Lilly press release, CNBC, Fierce Biotech

Lilly says it will initiate Phase 3 trials of the co-formulated, single-injection version using an optimized escalation schedule to reduce the gastrointestinal side effects. Registration of the trial on clinicaltrials.gov would confirm the program advanced on schedule.

2

Tolerability derails EloraTZP

Unlikely Resolves by End of 2029

Discussed by: New Scientist, commentary from Kevin Gade of Bahl & Gaynor

Gastrointestinal effects were more common with EloraTZP than tirzepatide alone, and dropout rates reached 27%. If the optimized Phase 3 schedule fails to fix tolerability, Lilly could delay, scale back, or abandon the combination.

3

EloraTZP wins FDA approval

Possible Resolves by End of 2030

Discussed by: New Scientist, citing researcher Lora Heisler on approval within a few years

If Phase 3 succeeds and dosing is well tolerated, the combination could reach the market within a few years, giving Lilly a weight-loss option that beats both Zepbound and Novo's CagriSema. Approval for treating type 2 diabetes or obesity would be the registration milestone.

4

Novo's CagriSema reaches market first

Possible Resolves by Q2 2028

Discussed by: DevDiscourse reporting on Novo's timeline

Novo Nordisk says it is on track to launch CagriSema, an amylin-GLP-1 combination, early in 2027, which would make it the first two-drug obesity treatment on the market. A launch would not stop Lilly's work on EloraTZP but would reset the competitive story.

5

Eloralintide wins approval as a single agent

Possible

Discussed by: Lilly's Thomas Seck, Clinical Trials Arena (ENLIGHTEN programme)

Lilly is running Phase 3 trials of eloralintide alone under the ENLIGHTEN programme. Seck said the amylin agonist appears to cause fewer gastrointestinal side effects than existing GLP-1 drugs, pending confirmation in those trials. Success would give Lilly a tolerated option for patients who cannot handle GLP-1 side effects.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

November 2023 to late 2024

Zepbound beats Wegovy in head-to-head trials (2023–2024)

Lilly's tirzepatide, sold as Zepbound for obesity, beat Novo's semaglutide-based Wegovy in a head-to-head trial, cementing dual GIP/GLP-1 agonism as more effective than GLP-1 alone. The FDA approved Zepbound for weight management in November 2023.

Then

Zepbound became a top-selling obesity drug and positioned Lilly as the category's leader.

Now

The rivalry pushed both companies toward combination therapies, with Lilly testing amylin and Novo developing CagriSema.

Why this matters now

EloraTZP extends the same escalation, adding an amylin pathway to a GIP/GLP-1 base to push weight loss beyond what tirzepatide alone achieves.

March 2005

Pramlintide, the first amylin drug (2005)

The FDA approved pramlintide (Symlin), the first amylin analog, for type 2 diabetes. It worked on the same hormone pathway EloraTZP now uses, but had to be injected with meals and frequently caused nausea.

Then

Symlin saw limited use, mostly as an add-on to insulin, and never became a major obesity treatment.

Now

The slow start guided development of selective amylin agonists like eloralintide, engineered to avoid calcitonin-receptor activity linked to side effects.

Why this matters now

EloraTZP revisits the amylin pathway with a more selective compound, suggesting why Lilly believes the pathway can finally deliver the weight loss pramlintide promised.

Sources

(18)
+12
PR Newswire CNBC Medical Xpress HCPLive Fierce Biotech New Scientist DevDiscourse BioSpace BioWorld MarketScreener Quartz ClinicalTrials.gov Stockwatch netzender Investing.com Brasil The Asia Business Daily Clinical Trials Arena CNBC